Biogen takes Creative Biolabs to court over antibody

Biogen and the University of Zurich have accused New York-based Creative Biolabs of unlawfully selling copies of Biogen’s aducanumab antibody.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Danish university sues Creative Biolabs over ‘antibody pirating’

9 December 2020 The University of Southern Denmark has accused biotech Creative Biolabs of infringing its patent-protected monoclonal antibody, HG-HYB 7-5.

Biotechnology

Roche stakes $2bn on UCB Alzheimer’s disease treatment

30 July 2020 Swiss company Roche has partnered with Belgium-based biopharmaceutical company UCB to develop an antibody treatment for people living with Alzheimer’s disease.

Americas

Five core IP legal principles in life sciences

9 July 2020 In the high stakes world of life sciences, the strength of a company’s IP portfolio can determine the value of a corporate transaction, argue Jonathan Harris and Nisan Zaghi of Axinn, and Ian Lodovice of Biogen.

More on this story

Americas

Danish university sues Creative Biolabs over ‘antibody pirating’

9 December 2020 The University of Southern Denmark has accused biotech Creative Biolabs of infringing its patent-protected monoclonal antibody, HG-HYB 7-5.

Biotechnology

Roche stakes $2bn on UCB Alzheimer’s disease treatment

30 July 2020 Swiss company Roche has partnered with Belgium-based biopharmaceutical company UCB to develop an antibody treatment for people living with Alzheimer’s disease.

Americas

Five core IP legal principles in life sciences

More on this story

Americas

Danish university sues Creative Biolabs over ‘antibody pirating’

9 December 2020 The University of Southern Denmark has accused biotech Creative Biolabs of infringing its patent-protected monoclonal antibody, HG-HYB 7-5.

Biotechnology

Roche stakes $2bn on UCB Alzheimer’s disease treatment

30 July 2020 Swiss company Roche has partnered with Belgium-based biopharmaceutical company UCB to develop an antibody treatment for people living with Alzheimer’s disease.

Americas

Five core IP legal principles in life sciences